Navigation Links
Treatment to benefit African infants at risk of endemic fever
Date:4/22/2012

Thousands of pre-school children in Africa could benefit from access to treatment for an endemic disease, after tests showed infants to be at high risk of infection.

Researchers tested hundreds of children aged between one and five in countries in sub-Saharan Africa where snail fever also known as bilharzia or schistosomiasis is endemic. Currently, infants are not regularly tested for infection as they are perceived to be at low risk of exposure to the water-borne disease and not to suffer severely from its ill-effects.

Scientists showed that in fact, infection rates are high among pre-school children. This may be because they often accompany their mothers to rivers and wells. Symptoms of the disease which can include impaired memory and thought as well as damage to internal organs and stunted growth are not always obvious.

The study found that a common snail fever drug, known as praziquantel, which is regularly given to older children and adults, can safely cure the infection in infants. The treatment is cheap and effective, curing infection and stopping progress of disease in a single dose.

Researchers from the University of Edinburgh carried out studies in Zimbabwe and their results were combined with work by other teams in Mali, Sudan, Egypt, Niger and Uganda. In a recent World Health Organisation report, the teams recommended that infants be included in treatment programmes, and their work is informing public health policy.

According to the WHO, snail fever affects 230 million people each year, most of whom are African. Some 33.5 million people were treated for the disease in 2010. Children are especially vulnerable because they make frequent contact with infected water.

Dr Francisca Mutapi, of the University of Edinburgh's School of Biological Sciences, who took part in the study, said: "Snail fever is a widespread disease of major health consequence in young children. Our study shows that infants are especially vulnerable to infection and should be included in public health treatment programmes."


'/>"/>

Contact: Catriona Kelly
catriona.kelly@ed.ac.uk
44-131-651-4401
University of Edinburgh
Source:Eurekalert

Related biology news :

1. Drug interactions wont exclude HCV transplant or HIV co-infected patients from treatment
2. As deadly cat disease spreads nationally, MU veterinarian finds effective treatment
3. Promising developments in early diagnosis and treatment of mesothelioma
4. Antipsychotic drug may be helpful treatment for anorexia nervosa
5. New discovery may lead to effective prevention and treatment of graft-versus-host dsease
6. Researcher who identifed genetic cause and possible treatment for Marfan syndrome honored
7. Penn research points to new way of preserving fertility for boys undergoing cancer treatment
8. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
9. New discoveries about brain-hand connection sought to improve therapies, treatments, prosthetics
10. Marshall University study may lead to new treatments for prostate cancer
11. Step forward in research into new treatments for brain edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company , ... Watson Ads, an industry-first capability in which consumers will be ... able to ask questions via voice or text and receive ... Marketers have long sought an advertising ... that can be personal, relevant and valuable; and can scale ...
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: